These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31713130)

  • 61. Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context.
    De Nicolò A; Stroffolini G; Antonucci M; Mula J; De Vivo ED; Cusato J; Palermiti A; Cariti G; Di Perri G; Corcione S; De Rosa FG; D'Avolio A
    Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680409
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis.
    Guest JF; Esteban J; Manganelli AG; Novelli A; Rizzardini G; Serra M
    PLoS One; 2017; 12(11):e0187792. PubMed ID: 29136035
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.
    Coyle V; Forde C; Adams R; Agus A; Barnes R; Chau I; Clarke M; Doran A; Grayson M; McAuley D; McDowell C; Phair G; Plummer R; Storey D; Thomas A; Wilson R; McMullan R
    Health Technol Assess; 2024 Mar; 28(14):1-101. PubMed ID: 38512064
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: A case series.
    Ben-Sassi K; Sarwar S
    J Glob Antimicrob Resist; 2024 Sep; 38():306-308. PubMed ID: 38821442
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift.
    Verastegui JE; Hamada Y; Nicolau DP
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1039-45. PubMed ID: 27248789
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Usefulness of dalbavancin in early discharge and nonhospitalization. It's time to throw your heart over the obstacle?
    Crapis M; Venturini S; Callegari A; Del Fabro G; Bramuzzo I; De Santi L; Pontoni E; Tonizzo M; Basso B
    Glob Reg Health Technol Assess; 2024; 11(Suppl 2):18-21. PubMed ID: 39100523
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dalbavancin Use in the Emergency Department Setting.
    Patel M; Smalley S; Dubrovskaya Y; Siegfried J; Caspers C; Pham V; Press RA; Papadopoulos J
    Ann Pharmacother; 2019 Nov; 53(11):1093-1101. PubMed ID: 31155916
    [No Abstract]   [Full Text] [Related]  

  • 68. Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.
    Simonetti O; Rizzetto G; Molinelli E; Cirioni O; Offidani A
    Ther Clin Risk Manag; 2021; 17():223-232. PubMed ID: 33790563
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
    Zhanel G; Silverman M; Malhotra J; Baxter M; Rahimi R; Irfan N; Girouard G; Dhami R; Kucey M; Stankus V; Schmidt K; Poulin S; Connors W; Tascini C; Walkty A; Karlowsky J
    J Glob Antimicrob Resist; 2024 Sep; 38():154-157. PubMed ID: 38908823
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.
    Smith JR; Roberts KD; Rybak MJ
    Infect Dis Ther; 2015 Sep; 4(3):245-58. PubMed ID: 26341488
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department.
    Almarzoky Abuhussain SS; Burak MA; Kohman KN; Jacknin G; Tart SB; Hobbs ALV; Adams DK; Nailor MD; Keyloun KR; Nicolau DP; Kuti JL
    BMC Health Serv Res; 2018 Dec; 18(1):932. PubMed ID: 30514295
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
    Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
    N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS.
    Valerio M; Veintimilla C; Rodríguez C; de la Villa S; Sánchez-Somolinos M; Cerezales M; Crespo C; Rodríguez S; Adán I; Chamorro E; Rosselló I; Muñoz P
    J Med Econ; 2023; 26(1):463-472. PubMed ID: 36950932
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.
    Li JZ; Willke RJ; Rittenhouse BE; Rybak MJ
    Surg Infect (Larchmt); 2003; 4(1):57-70. PubMed ID: 12744768
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections
    Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P
    J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial.
    López H; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Vidal G; Zitto T; Tang T
    Clin Ther; 2003 Jun; 25(6):1846-71. PubMed ID: 12860502
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy of Dalbavancin and Telavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections.
    Jagan N; Pendru R; Jyothinath K
    Maedica (Bucur); 2018 Sep; 13(3):208-212. PubMed ID: 30568740
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The current and future off-label uses of dalbavancin: a narrative review.
    De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
    [TBL] [Abstract][Full Text] [Related]  

  • 80. New agents approved for treatment of acute staphylococcal skin infections.
    Tatarkiewicz J; Staniszewska A; Bujalska-Zadrożny M
    Arch Med Sci; 2016 Dec; 12(6):1327-1336. PubMed ID: 27904526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.